Verastem, Inc. (LON: 0LOV)
London
· Delayed Price · Currency is GBP · Price in USD
5.24
-0.22 (-3.95%)
Jan 22, 2025, 7:08 PM BST
Verastem Revenue
Verastem had revenue of $10.00M USD in the twelve months ending September 30, 2024.
Revenue (ttm)
$10.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
$136.99K
Employees
73
Market Cap
205.83M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
Dec 31, 2019 | 17.46M | -9.26M | -34.67% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Verastem News
- 8 days ago - Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - Business Wire
- 9 days ago - Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire
- 10 days ago - Verastem Oncology announces debt refinancing with Oberland Capital - Seeking Alpha
- 10 days ago - Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - Business Wire
- 15 days ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 19 days ago - Verastem: Planning The PDUFA Run-Up - Seeking Alpha
- 20 days ago - Verastem: BLA Acceptance Puts Key Goals In Sight - Seeking Alpha
- 22 days ago - Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday? - Benzinga